Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate, ADS-5102, is being developed for a complication of Parkinson’s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as Ne...
2200 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $728.0K
Senior Vice President of Product Development
Total Annual Compensation: $561.5K
Compensation as of Fiscal Year 2013.
Adamas Pharmaceuticals, Inc. Key Developments
Actavis plc and Adamas Pharmaceuticals Inc. Announce FDA Approval of Namzaric
Dec 24 14
Actavis plc and Adamas Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric, formerly known as MDX-8704, is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on food to facilitate dosing for patients who may have difficulty swallowing. Namzaric will be available in two dosage strengths, 28/10 mg (memantine extended release/donepezil) and 14/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Memantine ER is the active ingredient in the currently marketed NAMENDA XR®, which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Donepezil is the active ingredient in ARICEPT®, which is indicated for the treatment of mild to severe dementia of the Alzheimer's type. Actavis and Adamas collaborated on the development of the fixed-dose combination and Actavis will have exclusive U.S. commercialization rights, while Adamas will retain exclusive commercialization rights outside of the U.S. Actavis expects to launch Namzaric in the U.S. in the second quarter of 2015.
Adamas Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015
Dec 15 14
Adamas Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.
Adamas Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:30 PM
Nov 18 14
Adamas Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Gregory T. Went, Chairman and Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|